Unicycive Therapeutics price target raised to $7.50 from $4 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Unicycive Therapeutics (UNCY) to $7.50 from $4 and keeps a Buy rating on the shares following the Q4 report. The firm views 2025 as a “likely transformational year” for Unicycive and the shares.